panitumumab (vectibix) Report issue

Biologics mAb Approved FDA Accelerated Approval FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$367.5930 - $1470.3487

United States

$858.8900 - $4867.2000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

abx-egf | abx-egf mab | abx-egf monoclonal antibody | amg 954 | e7.6.3 | immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal abx-egf heavy chain), disulfide with human monoclonal abx-egf light chain, dimer | l01xc08 | panitumumab | panitumumab antibody, human | vectibix

Organizations (220)

Research & Development (220)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (55)

Approved Indications (1)


 

Colorectal Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (55)


 

Adenocarcinoma (Phase 2)

Adenoma, Pleomorphic (Phase 2)

Anal Canal (Phase 1/Phase 2)

Biliary Tract Neoplasms (Phase 2)

Brain Neoplasms (Phase 1/Phase 2)

Breast Diseases (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Cholangiocarcinoma (Phase 2)

Colonic Neoplasms (Phase 4)

Colorectal Neoplasms ()

Dermatology (Phase 2)

Digestive System Neoplasms (Phase 1/Phase 2)

Drug Evaluation (Phase 2)

Edema (Phase 2)

Endometrial Neoplasms (Phase 2)

Epidermal Growth Factor (Phase 2)

Erythema (Phase 2)

Esophageal Neoplasms (Phase 3)

Exanthema (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Gallbladder Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Glioma (Phase 2)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 3)

Healthy Volunteers (Phase 1)

Inflammatory Breast Neoplasms (Phase 2)

Kidney Neoplasms (Phase 1)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Malignant Carcinoid Syndrome (Phase 2)

Microsatellite Instability (Phase 2)

Mutation (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms ()

Neoplasms, Second Primary (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pathology (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Proto-Oncogene Proteins B-raf (Phase 2)

ras Proteins (Phase 3)

Rectal Neoplasms (Phase 2)

Skin Diseases (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 222
  • # of Trial Organizations: 220

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue